<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="publisher-id">JCTH</journal-id><journal-title-group><journal-title>Journal of Clinical and Translational Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2225-0719</issn><issn pub-type="epub">2310-8819</issn><publisher><publisher-name>XIA &#x00026; HE Publishing Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9396313</article-id><article-id pub-id-type="publisher-id">JCTH.2021.00353</article-id><article-id pub-id-type="doi">10.14218/JCTH.2021.00353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Pluripotent Stem Cell-derived Strategies to Treat Acute Liver Failure: Current Status and Future Directions</article-title><alt-title alt-title-type="running-head-verso">Liu J. <italic>et al</italic>: Stem cell-derived technologies in treating ALF</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jingfeng</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="COR1" ref-type="corresp">*</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8509-0572</contrib-id></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Zhiming</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qingwen</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>1</label>Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen, Guangdong, China</aff><aff id="aff2"><label>2</label>Shenzhen Key Laboratory of Immunity and Inflammatory Diseases, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China</aff><aff id="aff3"><label>3</label>Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China</aff><aff id="aff4"><label>4</label>Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label><bold>Correspondence to</bold>: Jingfeng Liu, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, 1068 Xueyuan Avenue, Shenzhen University Town, Shenzhen, Guangdong, China. ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-8509-0572" ext-link-type="uri">https://orcid.org/0000-0002-8509-0572</ext-link>, Tel: +86-755-86392288, E-mail: <email>oscar1356@smu.edu.cn</email>; Qingwen Wang, Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, 1120 Lianhua Rd, Futian District, Shenzhen, Guangdong 518035, China. Tel: +86-755-83923333, E-mail: <email>wqw_sw@163.com</email></corresp><fn fn-type="financial-disclosure"><p>This research was supported by Shenzhen Key Laboratory of Inflammatory and Immunology Diseases (No. ZDSYS20200811143756018), China Postdoctoral Science Foundation (No. 2021M693290), the Key Program for Basic Research of Shenzhen Science and Technology Innovation Commission (No. JCYJ20200109140203849) and Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515111000).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflict of interests related to this publication.</p></fn><fn fn-type="con"><p>Study concept and design (JL, QW), acquisition of data (JL, ZY), analysis and interpretation of data (JL, ZY), drafting of the manuscript (JL), critical revision (JL, ZY, QW), critical funding (JL, QW), administration (JL, QW), technical or material support (JL), and study supervision (JL, QW).</p></fn></author-notes><pub-date pub-type="ppub"><day>28</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>9</day><month>3</month><year>2022</year></pub-date><volume>10</volume><issue>4</issue><fpage>692</fpage><lpage>699</lpage><history><date date-type="received"><day>22</day><month>8</month><year>2021</year></date><date date-type="rev-recd"><day>17</day><month>1</month><year>2022</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Liver disease has long been a heavy health and economic burden worldwide. Once the disease is out of control and progresses to end-stage or acute organ failure, orthotopic liver transplantation (OLT) is the only therapeutic alternative, and it requires appropriate donors and aggressive administration of immunosuppressive drugs. Therefore, hepatocyte transplantation (HT) and bioartificial livers (BALs) have been proposed as effective treatments for acute liver failure (ALF) in clinics. Although human primary hepatocytes (PHs) are an ideal cell source to support these methods, the large demand and superior viability of PH is needed, which restrains its wide usage. Thus, a finding alternative to meet the quantity and quality of hepatocytes is urgent. In this context, human pluripotent stem cells (PSC), which have unlimited proliferative and differential potential, derived hepatocytes are a promising renewable cell source. Recent studies of the differentiation of PSC into hepatocytes has provided evidence that supports their clinical application. In this review, we discuss the recent status and future directions of the potential use of PSC-derived hepatocytes in treating ALF. We also discuss opportunities and challenges of how to promote such strategies in the common applications in clinical treatments.</p></abstract><kwd-group><kwd>Acute liver failure</kwd><kwd>Hepatocyte transplantation</kwd><kwd>Human pluripotent stem cells</kwd><kwd>Bioartificial liver system</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Liver diseases, including acute liver failure (ALF) are a public health challenge worldwide, because of death caused by liver dysfunction.<xref rid="JCTH-D-21-00353-b1" ref-type="bibr">1</xref>&#x02013;<xref rid="JCTH-D-21-00353-b3" ref-type="bibr">3</xref> ALF is a severe condition with significant morbidity and mortality even for the patients without pre-existing liver disease. The causes of ALF vary geographically with viral infections of the liver, primarily hepatitis B, C, and E in developing countries and drug overdose-induced ALF, usually paracetamol (acetaminophen), in developed countries such as USA and parts of Europe.<xref rid="JCTH-D-21-00353-b4" ref-type="bibr">4</xref>&#x02013;<xref rid="JCTH-D-21-00353-b8" ref-type="bibr">8</xref> Because of the severity of ALF, there are few ways to prevent or cure patients other than orthotopic liver transplantation (OLT), which is now the only treatment that is considered effective to avoid the life-threatening complications caused by ALF.<xref rid="JCTH-D-21-00353-b9" ref-type="bibr">9</xref>&#x02013;<xref rid="JCTH-D-21-00353-b11" ref-type="bibr">11</xref> However, OLT is limited by the scarcity of available donor livers, complicated surgery procedures, and high financial burden.<xref rid="JCTH-D-21-00353-b12" ref-type="bibr">12</xref> Therefore, other than OLT and drug supplements for the maintenance of basic vital signs, there is a need for effective therapeutic treatments for ALF.</p><p>In recent years, hepatocytes transplantation (HT) and bioartificial liver (BAL) system have emerged as effective methods for the compensatory treatments of ALF related liver dysfunction.<xref rid="JCTH-D-21-00353-b13" ref-type="bibr">13</xref>&#x02013;<xref rid="JCTH-D-21-00353-b16" ref-type="bibr">16</xref> These two methods potentially build up the fundamental niche for host liver regeneration and decelerate the disease progression, which creates a bridging time for OLT. As reported, effective HT involves reconstitution of as much as 2.5% functional liver tissue in treating acute-on-chronic liver failure (ACLF).<xref rid="JCTH-D-21-00353-b17" ref-type="bibr">17</xref> Consistent with that, primary hepatocytes (PHs) are considered the ideal cell source for such treatments. Unfortunately, it remains a bottleneck to meet the demand of large quantity and clinical quality of PH from limited viable organ donation. To solve these problems, studies have focused on developing strategies using human pluripotent stem cell (PSC)-derived hepatic-like cells (HLCs), including hepato-blasts and hepatocytes. The differentiation of PSCs into clinical-grade HLCs has been studied.<xref rid="JCTH-D-21-00353-b18" ref-type="bibr">18</xref>&#x02013;<xref rid="JCTH-D-21-00353-b20" ref-type="bibr">20</xref> The aim of this review is to summarize the current opinions regarding the therapeutic effectiveness of PSC-derived HLC for ALF treatment and to discuss recent progresses in preclinical and clinical treatments and challenges, which need to be improved in using PSC-derived HLC (<xref rid="JCTH-D-21-00353-f1" ref-type="fig">Fig. 1</xref>).</p><fig position="float" id="JCTH-D-21-00353-f1"><label>Fig. 1</label><caption><title>Producing pluripotent stem cell (PSC)-derived hepatic-like cells (HLCs) for use in bioartifical liver support and hepatocyte transplantation applications.</title><p>The advantage of using PSC derived of HLC is their unlimited proliferation potential, which addresses both the shortage of viable donor livers and primary hepatocytes. By differentiating PSC (hESCs or iPSCs) or genome edited PSC into HLC, we can obtain HLCs of the required quantity and quality for BAL and HT in severe liver disease (e.g., ALF, ACLF, and ESLD). After BAL or HT treatment, the ideal outcome is either graft expansion and the regeneration of the host liver or bridging to OLT. ALF, acute liver failure; ACLF, acute on chronic liver failure; BAL, bioartificial liver; ESLD, end-stage liver disease; hESC, human embryonic stem cell; HLC, hepatic-like cell; HT, hepatocyte transplantation; iPSC, induced pluripotent stem cell; OLT, orthotopic liver transplantation; PSC, pluripotent stem cell.</p></caption><graphic xlink:href="JCTH-10-692-g001" position="float"/></fig></sec><sec id="s2"><title>Characteristics of ALF</title><p>ALF is characterized by severe injury of liver cells that has a rapid onset and leads to a frequent fatal outcome, with up to 30% mortality.<xref rid="JCTH-D-21-00353-b21" ref-type="bibr">21</xref> Paracetamol overdose and autoimmunity caused liver injuries are the most frequent causes in developed countries. HBV infection is the primary cause of ALF in developing countries.<xref rid="JCTH-D-21-00353-b2" ref-type="bibr">2</xref> Paracetamol toxicity, which induces mitochondrial oxidant stress-related cell death and sterile inflammatory responses in hepatocytes, accounts for more than 46% of the ALF cases in the USA.<xref rid="JCTH-D-21-00353-b22" ref-type="bibr">22</xref> At the early stage of paracetamol-induced liver injury, treatment with N-acetyl-cysteine or 4-methylpyrazole (fomepizole) can effectively control the progress.<xref rid="JCTH-D-21-00353-b23" ref-type="bibr">23</xref> However, at later stages, drugs are no longer effective to slow disease progression, which leaves OLT as the last option to save such patients. HBV infection has plagued China for a long time, and is involved in 84% of hepatocellular carcinoma and 77% of liver cirrhosis patients annually.<xref rid="JCTH-D-21-00353-b6" ref-type="bibr">6</xref> Control of HBV is fundamental to preventing ALF. Anti-HBV drugs focus on how to slow the replication of viral DNA, but completely eliminating HBV DNA is hard to achieve, and is the main reason of HBV relapse and progression.<xref rid="JCTH-D-21-00353-b24" ref-type="bibr">24</xref>,<xref rid="JCTH-D-21-00353-b25" ref-type="bibr">25</xref> Once the HBV replication is out of control, there&#x02019;s a large chance to cause ALF. The pathology and autopsy of ALF patients often shows widespread hepatic apoptosis and necrosis with few viable hepatocytes remaining, which leads to the failure of liver regeneration. To save ALF patients, the question to answer is how to buy time for patients to carry out liver regeneration.</p><p>Treatment of ALF must deal with systemic complications including the release of pro-inflammatory cytokines, multiple organ failure, and a hypotensive environment. Hepatic encephalopathy frequently appears because they hepatocyte death results in aberrant liver function and toxins that travel to the brain and affect the brain function. Although L-ornithine-L-aspartate and ornithine phenylacetate inhibit ammonia synthesis to relieve symptoms, OLT is current, y the last chance for ALF patients currently. Development of novel treatments of ALF patients is currently urgent.</p></sec><sec id="s3"><title>Current knowledge of the treatments for ALF</title><p>In addition to the basic symptomatic supporting treatments to stabilize the vital signs, cell therapy-based supplement for liver regeneration and bioartificial liver (BAL) support system have been developed as effective tools for ALF patients. Both of these methods require a large quantity of viable hepatocytes.</p></sec><sec id="s4"><title>BAL system</title><p>Before the emergence of BAL, abiotic artificial liver therapy, including plasmapheresis, hemoperfusion absorption, and venous hemodiafiltration, were used as clinical treatments with limited success.<xref rid="JCTH-D-21-00353-b26" ref-type="bibr">26</xref>,<xref rid="JCTH-D-21-00353-b27" ref-type="bibr">27</xref> The molecular adsorbent recirculating system and Prometheus system are widely used non-bioartificial liver systems with benefits for ALF patients.<xref rid="JCTH-D-21-00353-b28" ref-type="bibr">28</xref>,<xref rid="JCTH-D-21-00353-b29" ref-type="bibr">29</xref> However, as it relies on exogenous detoxification, is not able to provide an environment needed for hepatic regeneration as it is complicated to mimic all the functions of host hepatocytes. BAL systems include functional hepatocytes in a bioreactor that simulates the function of a normal human liver. To a large extent, it can not only remove the toxic substances but also provide functions such as synthesis and metabolism, which temporarily replace the function of the damaged liver in order to survive from the fatal onsets of ALF.<xref rid="JCTH-D-21-00353-b16" ref-type="bibr">16</xref>,<xref rid="JCTH-D-21-00353-b30" ref-type="bibr">30</xref> The indispensable factor within the BAL system are the functional hepatocytes. The quality of functional hepatocytes, the ease of obtaining them and safety are decisive in determining whether the BAL can play an important role in clinical treatment.</p><p>Prior to this, the main sources of functional hepatocytes were primary liver cells, porcine liver cells, human liver cancer cell lines like HepG2, HepaRG, and immortalized human liver cell lines like L-02. Human PH are the best for use in BALs, but organ sources are limited, and it is difficult to obtain a sufficient number of human PH for BALs. Porcine liver cells are used because of their functions, abundant source, and the easy accesses. For example, the AMC artificial liver system using porcine liver cells successfully helped 12 patients with ALF to gain time for OLT. One patient no longer needed because of the effectiveness of therapy.<xref rid="JCTH-D-21-00353-b31" ref-type="bibr">31</xref>,<xref rid="JCTH-D-21-00353-b32" ref-type="bibr">32</xref> The HepaAssist system, which uses porcine liver cells, is the only BAL system that has been a investigated in a multicenter randomized controlled clinical trial in the USA. Although it has achieved encouraging therapeutic effects in phase III clinical trials, it has not yet obtained Federal Drug Administration approval. It is underlying safety concerns including heterogeneous immune rejection and animal-derived virus infections have made it difficult to obtain regulatory approval.<xref rid="JCTH-D-21-00353-b33" ref-type="bibr">33</xref> The superiority of human liver cancer cell lines and immortalized human liver cell lines is that they can proliferate indefinitely <italic>in vitro</italic>. However, their functions are greatly compromised and there is a potential tumorigenic risk, which limits their application prospects. For example, the Vital Therapies artificial liver system, which uses C3A liver cancer cells, failed a phase III clinical trial because of poor therapeutic effects, even though the effectiveness in animal experiments was good.<xref rid="JCTH-D-21-00353-b34" ref-type="bibr">34</xref>,<xref rid="JCTH-D-21-00353-b35" ref-type="bibr">35</xref> Therefore, to obtain a large quantity and clinical-grade quality of functional hepatocytes is the major hindrance for BAL.</p><p>Nowadays, in the research of regenerative medicine, PSC has received much attention due to the potential to be differentiated into functional hepatocytes as the source of seed cells in the BAL system. Precise differentiation of human embryonic stem cell (hESCs) or induced pluripotent stem cell (iPSCs) into HLC has been achieved and improved tremendously. In addition, with the appearance of 3D culturing system, hepatic organoid formation brings out more mature HLC, which owns comprehensive functions.<xref rid="JCTH-D-21-00353-b36" ref-type="bibr">36</xref>,<xref rid="JCTH-D-21-00353-b37" ref-type="bibr">37</xref> Moreover, Lijian Hui of Shanghai also successfully transdifferentiated human fibroblasts into human hepatocytes (hiHep), and overexpressed SV40 Large T through gene editing, thus obtaining the ability to be expanded <italic>in vitro</italic>, providing a potential cell source for BAL.<xref rid="JCTH-D-21-00353-b38" ref-type="bibr">38</xref> This technology also successfully conducted a clinical trial of a bioartificial liver in 2016, and achieved good therapeutic effects, which greatly improved the confidence to promote hiHep into the clinic applications. In addition, bioreactors, as the key devices in BAL system, are able to provide a favorable proliferative and metabolic platform for a large-scale liver cell culture and storage.<xref rid="JCTH-D-21-00353-b39" ref-type="bibr">39</xref> For example, a fluidized-bed bioreactor with alginate-based spherical beads is able to scale up 10<sup>11</sup> liver cells culture and retains their hepatic functions.<xref rid="JCTH-D-21-00353-b40" ref-type="bibr">40</xref> Yet the challenge is to extend such design to clinical applications.</p></sec><sec id="s5"><title>Hepatocyte transplantation (HT)</title><p>The concept of HT therapy was first described by scientists in the early 1970s. After more than 20 years of development, HT therapy was translated from animal experiments to clinical trials, and was shown to be effective in ALF, or acute-on-chronic liver failure (<xref rid="JCTH-D-21-00353-t1" ref-type="table">Table 1</xref>).<xref rid="JCTH-D-21-00353-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-21-00353-b41" ref-type="bibr">41</xref>&#x02013;<xref rid="JCTH-D-21-00353-b45" ref-type="bibr">45</xref> HT has several key therapeutic advantages. (1) It is less invasive OLT surgery and can be performed multiple times. (2). The patient&#x02019;s liver is preserved and retains its ability to regenerate itself. (3) With the development of gene editing and stem cell technology, HT can be coupled with targeted genome modifications, realizing individualized and precise treatment.<xref rid="JCTH-D-21-00353-b15" ref-type="bibr">15</xref>,<xref rid="JCTH-D-21-00353-b46" ref-type="bibr">46</xref> These advantages are not available in OLT or BAL support systems. So far, many liver diseases have undergone clinical trials of HT treatment, laying the foundation for clinical promotion and application.</p><table-wrap position="float" id="JCTH-D-21-00353-t1"><label>Table 1</label><caption><title>Clinical use of hepatocyte transplantation to treat acute liver failure (ALF)</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Time (year)</th><th align="left" rowspan="1" colspan="1">Number of recipients</th><th align="left" rowspan="1" colspan="1">Delivery route</th><th align="left" rowspan="1" colspan="1">Outcomes</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Drug-induced ALF</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;1999</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Portal vein</td><td align="left" valign="top" rowspan="1" colspan="1">2 Deaths: days 4 and 35</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b41" ref-type="bibr">41</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2000</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">intrasplenic</td><td align="left" valign="top" rowspan="1" colspan="1">3 Deaths: 6 h, days 14, and 20</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b42" ref-type="bibr">42</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2006</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">Intrasplenic and portal vein</td><td align="left" valign="top" rowspan="1" colspan="1">3 Deaths: days 1, 3, 18; 2 OLT: days 2 and 10; 1: Full recovery</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b43" ref-type="bibr">43</xref>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Hepatitis virus-induced ALF</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2000</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">Intrasplenic</td><td align="left" valign="top" rowspan="1" colspan="1">1 Full recovery</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b45" ref-type="bibr">45</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2000</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Intrasplenic and portal vein</td><td align="left" valign="top" rowspan="1" colspan="1">2 Deaths: 18 h and day 52</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b42" ref-type="bibr">42</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2006</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Portal vein</td><td align="left" valign="top" rowspan="1" colspan="1">2 Deaths: days 2 and 7</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b43" ref-type="bibr">43</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2010</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">Portal vein</td><td align="left" valign="top" rowspan="1" colspan="1">1 Death: day 11</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b44" ref-type="bibr">44</xref>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Acute-on-chronic liver failure</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;2014</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">Intrasplenic</td><td align="left" valign="top" rowspan="1" colspan="1">3: Full recovery; 3 Death: 2.5&#x02013;12 months; 1: OLT</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00353-b17" ref-type="bibr">17</xref>
</td></tr></tbody></table></table-wrap><p>How to gain time is a significant issue for ALF patients. For one thing, HT helps patients to regenerate their own livers, providing a proliferative niche for transplanted hepatocytes. While OLT is inevitable, HT plays a role as a transitional bridge connecting patients with an appropriate donor liver. In animal models of drug-induced ALF, HT significantly improves survival. In clinical trials, there have been more than 40 cases of ALF caused by drugs or viral infections treated by HT worldwide.<xref rid="JCTH-D-21-00353-b47" ref-type="bibr">47</xref>,<xref rid="JCTH-D-21-00353-b48" ref-type="bibr">48</xref> Although, they were not multicenter randomized controlled trials and the delivery method, volume of transplanted cells, and cell sources were not standardized, which makes them difficult to compare statistically, most patients responded well to treatment, with prolonged survival time, bridging to OLT, and even fully recovery (<xref rid="JCTH-D-21-00353-t1" ref-type="table">Table 1</xref>).<xref rid="JCTH-D-21-00353-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-21-00353-b41" ref-type="bibr">41</xref> The limited clinical data fully confirms the therapeutic effect of HT, but it needs to be further standardized and unified.</p></sec><sec id="s6"><title>PSC-derived hepatocytes</title><p>With both BAL support or HT treatment, the key to success is the quality and quantity of functional liver cells. Human PSCs, including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), have unlimited proliferation ability and the pluripotency to differentiate into any somatic cell type. Therefore, the differentiation of PSCs into HLCs with similar gene expression profiles and functions as human hepatocytes can, to a large extent, solve the problem of limited sources of functional hepatocytes. Recent advances in stem cell research have found methods that have increased the ease of inducing <italic>in vitro</italic> differentiation into HLCs. However, often not more than 10<sup>9</sup>&#x02013;10<sup>10</sup> the hepatocytes are available for treatment, which is a barrier between PSC differentiation and clinical application. One of the obstacles is that the efficiency of differentiation is limited, which often accompanied by the risk of incomplete differentiation or incorrect cell fates, resulting in unpredictable safety issues. Additionally, the current hepatocyte culture system has not been well developed, which is hard to maintain the proliferation ability and the functions of cultured hepatocytes at the same time. Therefore, we need to reach a more comprehensive and in-depth understanding of the molecular mechanisms of direct differentiation of PSC into HLC, to establish an efficient and stable differentiation system. We need to find ways to culture and expand hepatocytes <italic>in vitro</italic> to obtain a large number of clinical-grade hepatocytes, which is of great significance for the treatment of ALF by BAL and HT. The paragraphs below review the current status and progress of PSCs used for the treatment of ALF.</p></sec><sec id="s7"><title>Differentiation of PSCs into HLCs</title><p>The study of precise differentiation of PSC into HLC <italic>in vitro</italic> is mainly through simulating the development of human liver, which is accomplished by adding growth factors and small molecules that regulate the related signal pathways. Methods described in the available studies can be used to induce the differentiation of PSC into definitive endoderm (DE), hepatoblasts (HB), and mature hepatic cells, i.e. HLCs. Although the specific induction schemes adopted by different research groups are not the same, the basic method is: (1) induction of DE cells by activin-A; (2) Transformation of DE to HB by treatment with FGF, BMP, and HGF; and (3) use of OSM and dexamethasone (DEX) to induce maturation of HB into HLC (<xref rid="JCTH-D-21-00353-f2" ref-type="fig">Fig. 2</xref>).<xref rid="JCTH-D-21-00353-b49" ref-type="bibr">49</xref></p><fig position="float" id="JCTH-D-21-00353-f2"><label>Fig. 2</label><caption><title>Introduction of the differentiation of human pluripotent stem cells (hPSCs) into mature hepatocyte-like cells (HLCs).</title><p>Adapting hPSCs with activin-A is a well-known protocol for definitive endoderm (DE) induction. IDE-1 and IDE-2 are small molecules that can replace activin-A, which is an easier and inexpensive way of induction. The combination of growth factors for hepatoblast (HB) induction is well studied. Hepatic-like cell (HLC) induction and maturation is the last step for a successful differentiation. This step can be induced by dexamethasone (DEX) and oncostatin M (OSM). Small molecules could be developed for use in clinical applications.</p></caption><graphic xlink:href="JCTH-10-692-g002" position="float"/></fig><p>The induction of DE is the first step of differentiation and is a key step that determines the final differentiation efficiency. The most frequently used method is the induction of PSC to form DE cells by activin-A. The underlying mechanism is activation of the Nodal signaling pathway, which simulating the early steps of liver development <italic>in vivo</italic>.<xref rid="JCTH-D-21-00353-b50" ref-type="bibr">50</xref>&#x02013;<xref rid="JCTH-D-21-00353-b52" ref-type="bibr">52</xref> Some studies have reported that inhibiting the PI3K signaling pathway was a prerequisite for the effective use of activin-A for DE induction. Adding PI3K signaling pathway inhibitors improves the efficiency of DE differentiation.<xref rid="JCTH-D-21-00353-b53" ref-type="bibr">53</xref> Adding a rho kinase (ROCK) inhibitor at that stage reduces cell apoptosis to a certain extent, which improves cell survival and differentiation efficiency. Compared with the complex signaling pathways regulated at the DE stage, the regulation of the differentiation of HB and HLC cells is relatively clear. <italic>In vivo</italic> studies of liver development, <italic>in-vitro</italic> coculture studies and the single-cell sequencing have shown that the transforming growth factor beta (TGF-&#x003b2;), Wnt and NOTCH signaling pathways are the pathways most involved in the induction of DE cells by growth factors such as BMP, FGF, and HGF. This step avoids the establishment of an incorrect cell fate (e.g., bile duct or pancreas cells) and improves the purification of HLC at the final stage.<xref rid="JCTH-D-21-00353-b54" ref-type="bibr">54</xref></p><p>Differentiation induced by growth factors is recognized as an efficient method of obtaining functional HLCs, but growth factors are expensive and difficult to store, which limits their use for large-scale production of HLCs. In addition, most growth factors are protein products containing animal components that may cause adverse reactions associated with clinical use. In that context, a combination of small molecules can be used to replace the growth factors and obtain functional HLC with high efficiency. Properties of the small molecules include the ability to freely penetrate cell membranes, stable structures, no immunogenicity, low cost, and wide variety. The use of small-molecule compounds is expected to become a safer and more effective method of inducing clinical-grade HLCs. Recent reports by multiple research groups have described the use of small molecules to induce differentiation into HLCs. IDE1 and IDE2 are small molecules that can efficiently induce PSC to form DE, act much as activin-A by simulating the Nodal signaling pathway.<xref rid="JCTH-D-21-00353-b55" ref-type="bibr">55</xref> In the HB stage, glycogen synthase kinase (GSK)-3&#x003b2; is used to simulate the Wnt pathway to guide DE to a hepatic fate and not bile duct fate.<xref rid="JCTH-D-21-00353-b56" ref-type="bibr">56</xref>,<xref rid="JCTH-D-21-00353-b57" ref-type="bibr">57</xref> Recently, Asuma <italic>et al</italic>.<xref rid="JCTH-D-21-00353-b20" ref-type="bibr">20</xref> reported the use of small molecules to differentiate hESCs into HLC. A comparison of HLCs induced by small molecules and those derived from growth factors showed a considerable number of functions, such as albumen (ALB) secretion, CYP450 activity which metabolizes drugs and enzymes. In addition, Pan <italic>et al</italic>.<xref rid="JCTH-D-21-00353-b58" ref-type="bibr">58</xref> introduced an improved combination of small molecules for robust HLC induction. The use of small molecules activity has promising prospects, but further research is needed to develop more stable and efficient combinations of small molecules to increase effectiveness and safety for adapting to clinical use.</p><p>Functional HLCs can be obtained by direct differentiation of PSCs. There are also reports of transdifferentiating somatic cells to obtain functional HLCs. Hui, L <italic>et al</italic>.<xref rid="JCTH-D-21-00353-b38" ref-type="bibr">38</xref> reported that after human fibroblasts overexpressing the transcription factors FOXA3, HNF1&#x003b1; and HNF4&#x003b1; can be transdifferentiated into HLCs and perform a series of functions similar to those of PHs. Transdifferentiation provides another way to source of HLC, but it safety needs further verification, as such transcriptional factors are known to participate in the carcinogenesis of hepatocellular carcinoma.</p></sec><sec id="s8"><title><italic>In vitro</italic> expansion of HLCs</title><p>Obtaining HLCs from PSCs has been validated by multiple research groups, proving its reproducibility and efficiency. However, owing to the required volume of cells for transplantation for clinical applications, relying on the differentiated HLC is not enough. As a result, how to expand hepatocytes <italic>in vitro</italic> has attracted widespread attention in recent years. Hepatocytes are terminally differentiated cells, which makes them difficult to culturing <italic>in vitro</italic> and maintain their inherent functional properties. Hui Lijian <italic>et al</italic>.<xref rid="JCTH-D-21-00353-b59" ref-type="bibr">59</xref> reported that a combination of small molecules, adding Wnt3a to hepatocyte medium and removing Rspo1, Noggin, and forskolin increased the fold-expansion of human hepatocytes by 10,000 times. However, they found that the expanded hepatocytes had a bidirectional differentiation potential that placed them between HPCs and mature hepatocytes. It seems to be a complicated task to expand hepatocytes <italic>in vitro</italic>, and the research is focused on the expansion of hepatic progenitor cells like HBs that still have some degree of stemness.</p><p>Compared with mature hepatocytes, HBs has a stronger proliferation ability and the potential of rapid differentiation into both hepatocytes and bile duct cells.<xref rid="JCTH-D-21-00353-b60" ref-type="bibr">60</xref>&#x02013;<xref rid="JCTH-D-21-00353-b63" ref-type="bibr">63</xref> Amplifying PSC-derived HBs is an ideal alternative source of hepatocytes. On the one hand, it is feasible to develop the proliferation potential of HB, and on the other hand, amplified HBs can be frozen to establish a cell bank, acting as seed cells that could be rapidly obtained for functional HLC differentiation. Recent reports have found that multiple small-molecule compounds are suitable for amplifying HB, such as the GSK-3&#x003b2; inhibitor CHIR99021, the TGF-&#x003b2; signaling pathway inhibitor A83-01, and the ROCK inhibitor Y27632. A recent study combined small molecules to simultaneously regulate the BMP/WNT/TGF-&#x003b2;/Hedgehog pathway, which not only maintains the stemness of HBs, but also retains their proliferative capacity. The HBs amplified by the combination had therapeutic effectiveness after transplantation into ALF-model mice.<xref rid="JCTH-D-21-00353-b64" ref-type="bibr">64</xref>,<xref rid="JCTH-D-21-00353-b65" ref-type="bibr">65</xref> Large-scale expansion of HBs, would be a major step in producing the HLCs in the quantity and with the quality required for clinical development and application.</p></sec><sec id="s9"><title>Clinical benefits of PSC-derived cell therapy</title><p>Much effort has been made worldwide to promote PSC-derived methods to cure chronic and acute illness. Induced PSC-derived retinal pigment epithelium cells have used clinically to cure patients with macular degeneration, with good outcomes 1 year after transplantation, which supports the use of PSC-derived cells in clinical applications.<xref rid="JCTH-D-21-00353-b66" ref-type="bibr">66</xref> The use of PSC-derived HLC for ALF, HT, and BAL applications would serve as a promising tool for clinical alternatives. The clinical indications and benefits of PSC-derived cell therapies for treating ALF or end-stage liver disease are summarized below.</p><sec id="s9a"><title>Modulating the regeneration niche</title><p>A positive outcome requires that HT promotes sufficient regeneration of the host liver. Besides increasing the homing and engraftment of transplanted hepatocytes, modulating the injury niche to include host immune responses such as the macrophage activation and cytokine release,<xref rid="JCTH-D-21-00353-b67" ref-type="bibr">67</xref>,<xref rid="JCTH-D-21-00353-b68" ref-type="bibr">68</xref> is also an important benefit of using PSC-derived HLCs. Unlike PH-derived HLCs, as hypoimmunogenic PSC-derived HLCs would modulate the host immune recruitment to restrain systemic inflammation. For example, phagocytosis mediated by macrophage activation might be limited by the CD47-SIRP&#x003b1; axis if PSC-derived HLCs overexpressing CD47 were transplanted.<xref rid="JCTH-D-21-00353-b69" ref-type="bibr">69</xref>&#x02013;<xref rid="JCTH-D-21-00353-b72" ref-type="bibr">72</xref> Such clinical applications could be useful in a broader scope of liver disease and not limited to ALF.</p></sec><sec id="s9b"><title>Transplantation feasibility and safety</title><p>Even if the shortage of donor livers could be solved, OLT is still a challenging procedure with risks including intraoperative bleeding, postsurgical cardiovascular dysfunction, and unavoidable death.<xref rid="JCTH-D-21-00353-b73" ref-type="bibr">73</xref>,<xref rid="JCTH-D-21-00353-b74" ref-type="bibr">74</xref> PSC-derived HT is a safer alternative with infusion that does not require major surgery and the possibility of multiple transplantation procedures.<xref rid="JCTH-D-21-00353-b75" ref-type="bibr">75</xref> Improvements in cell culture would make PSC-derived HLCs are a good alternative source of hepatocytes compared with PHs. The feasibility of PSC-derived HLCs is not limited by lack of a large quantity of HLCs, which can be cryopreserved to ensure a constantly available cell source for emergency treatment of ALF patients.<xref rid="JCTH-D-21-00353-b76" ref-type="bibr">76</xref>,<xref rid="JCTH-D-21-00353-b77" ref-type="bibr">77</xref></p></sec></sec><sec id="s10"><title>Individualized treatment</title><p>PSC-derived HLCs combined with Crispr/Cas9 genome editing and PSC differentiation would allow generating multiple PSC cell lines that met individual patient requirements or those of the primary illness.<xref rid="JCTH-D-21-00353-b78" ref-type="bibr">78</xref>,<xref rid="JCTH-D-21-00353-b79" ref-type="bibr">79</xref> For instance, the HBV-induced liver disease could theoretically be corrected by transplantation with HBV receptor (NTCP) knock-out or ectopic expression of NTCP variants in HLCs derived from edited PSCs.<xref rid="JCTH-D-21-00353-b80" ref-type="bibr">80</xref>,<xref rid="JCTH-D-21-00353-b81" ref-type="bibr">81</xref> Following transplantation in such patients, HBV could not enter hepatocytes as they lacked the receptor, which would avoiding the recurrence of HBV. Treatment might thus be adjusted depending on the pathophysiology of the primary illness that caused ALF.</p></sec><sec id="s11"><title>Challenges of current PSC based options</title><p>Clinical trials of HT and BAL support systems are ongoing, and strive to promote the two therapeutic methods with broad application prospects in clinical treatment. However, the novelty of the methods and the complexity of ALF, are challenging, and can be summarized as follows:</p><list list-type="order"><list-item><p>The lack of rigorous clinical trials makes it difficult to achieve a unified and standardized treatment. Most ALF patients indicated for HT and BAL are in a life-threatening stage of disease and require urgent treatment intervention. It is not possible for multiple centers to formulate detailed treatment procedures in time, which makes it difficult to reach a consensus. Standardized treatment indications, treatment procedures, countermeasures for complications, and the introduction of appropriate treatment guidelines are the prerequisites for the adoption of HT and BAL as clinical applications.</p></list-item><list-item><p>The key requirement of these two treatments is the quantity and quality of functional liver cells. No matter which method is used to obtain functional liver cells, an inevitable core problem is the immunogenicity of the cells. At present, adjuvant immunosuppressive agents or pretransplant radiotherapy are used in patients receiving HT, to suppress the patient&#x02019;s immune system and protect the transplanted cells. Once the immune system is suppressed, the patient is exposed to risks of tumorigenesis and infection. Recently, hypoimmunogenic PSC have been developed to overcome the issue of immune rejection. Through knocking out human lymphocyte antigen (HLA) Class I and II molecule accompanied by overexpression of the natural killer (NK) cell specific inhibition receptor (HLA-E) might help to evade host immune surveillance.<xref rid="JCTH-D-21-00353-b82" ref-type="bibr">82</xref>,<xref rid="JCTH-D-21-00353-b83" ref-type="bibr">83</xref> Human embryonic stem cells overexpressing CTLA4-Ig and PD-L1 are immune-evasive and have shown therapeutic effectiveness in a humanized mouse model of acute liver injury.<xref rid="JCTH-D-21-00353-b84" ref-type="bibr">84</xref>,<xref rid="JCTH-D-21-00353-b85" ref-type="bibr">85</xref> Further research should be carried out to elucidate the underlying mechanism. Its safety should not be neglected as the risk of tumor formation increases without host immune recognition. The development of novel immune tolerance strategies is of great significance for HT therapy.</p></list-item><list-item><p>Improvement of transplanted-cell engraftment and homing needs to be studied. After the liver is damaged, hepatic stellate cells are activated, become fibroblasts, deposit collagen that makes it difficult for transplanted cells to enter damaged regions of the liver. Different routes of delivery have been validated, among which splenic transplantation and hepatic portal vein are typically used in clinical treatments. There are three ways of delivery via the portal vein, ultrasound guided intrahepatic portal vein puncture, transcutaneous splenic vein puncture, and intrahepatic portosystemic shunt via the hepatic venous system.<xref rid="JCTH-D-21-00353-b35" ref-type="bibr">35</xref> However, the procedures are associated with risks of portal vein hypertension, bleeding, or thrombosis.<xref rid="JCTH-D-21-00353-b86" ref-type="bibr">86</xref> Alternate routes include the hepatic artery, which has a higher blood flow velocity and lower thrombosis formation risk.<xref rid="JCTH-D-21-00353-b87" ref-type="bibr">87</xref> More clinical data should be collected to choose the appropriate routes of delivery. Coupling nanomaterials and HT is a novel opinion that would improve the viability, homing, and engraftment of transplanted hepatocytes.<xref rid="JCTH-D-21-00353-b88" ref-type="bibr">88</xref>,<xref rid="JCTH-D-21-00353-b89" ref-type="bibr">89</xref> Micro-encapsulated HLC patches or decellularized liver scaffolds would avoid intravenous or arterial injection.<xref rid="JCTH-D-21-00353-b90" ref-type="bibr">90</xref>&#x02013;<xref rid="JCTH-D-21-00353-b92" ref-type="bibr">92</xref> Increasing the rate of homing of transplanted cells is a guarantee for the clinical therapeutic effectiveness of HT and needs further validation.</p></list-item></list></sec><sec id="s12"><title>Concluding remarks</title><p>In summary, HT and BAL support have bright prospects and application value in the treatment of ALF. PSC-derived HLCs have the potential for wide clinical application, but demonstration of effectiveness and lack of complications are still needed. The use of humanized immune system animal models can provide more accurate immune-response data for HT studies of reducing the immunogenicity of transplanted cells, establishing immune tolerance strategies, and safety. Last but not least, the combining various therapies for ALF treatment is a future trend.</p></sec></body><back><sec id="s12a1"><title>Data sharing statement</title><p>All data are available upon reasonable request.</p></sec><ref-list><title>References</title><ref id="JCTH-D-21-00353-b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Causes and outcomes of acute liver failure in China</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>e80991</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0080991</pub-id><pub-id pub-id-type="pmid">24278360</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>WY</given-names></name><name><surname>Xu</surname><given-names>BY</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>XB</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Acute-on-Chronic Liver Failure in China: Rationale for Developing a Patient Registry and Baseline Characteristics</article-title><source>Am J Epidemiol</source><year>2018</year><volume>187</volume><issue>9</issue><fpage>1829</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1093/aje/kwy083</pub-id><pub-id pub-id-type="pmid">29762630</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Incidence and Etiology of Drug-Induced Liver Injury in Mainland China</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><issue>8</issue><fpage>2230</fpage><lpage>2241.e11</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.02.002</pub-id><pub-id pub-id-type="pmid">30742832</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>NK</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global liver disease burdens and research trends: Analysis from a Chinese perspective</article-title><source>J Hepatol</source><year>2019</year><volume>71</volume><issue>1</issue><fpage>212</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.03.004</pub-id><pub-id pub-id-type="pmid">30871980</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WJ</given-names></name><name><surname>Xiao</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>HQ</given-names></name><name><surname>Niu</surname><given-names>JQ</given-names></name><name><surname>Gao</surname><given-names>YH</given-names></name></person-group><article-title>Growing burden of alcoholic liver disease in China: A review</article-title><source>World J Gastroenterol</source><year>2019</year><volume>25</volume><issue>12</issue><fpage>1445</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i12.1445</pub-id><pub-id pub-id-type="pmid">30948908</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Elizabeth</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name></person-group><article-title>Epidemiology of hepatitis B and associated liver diseases in china</article-title><source>Chin Med Sci J</source><year>2013</year><volume>27</volume><issue>4</issue><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/s1001-9294(13)60009-7</pub-id><pub-id pub-id-type="pmid">23294591</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Xin</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure</article-title><source>Gut</source><year>2018</year><volume>67</volume><issue>12</issue><fpage>2181</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314641</pub-id><pub-id pub-id-type="pmid">28928275</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>RH</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Sheng</surname><given-names>JF</given-names></name></person-group><article-title>Acute-on-chronic liver failure in chronic hepatitis B: an update</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2018</year><volume>12</volume><issue>4</issue><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1080/17474124.2018.1426459</pub-id><pub-id pub-id-type="pmid">29334786</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzoni</surname><given-names>A</given-names></name><name><surname>Pardi</surname><given-names>C</given-names></name><name><surname>Bortoli</surname><given-names>M</given-names></name><name><surname>Uncini Manganelli</surname><given-names>C</given-names></name><name><surname>Vanacore</surname><given-names>R</given-names></name><name><surname>Urciuoli</surname><given-names>P</given-names></name><etal/></person-group><article-title>High-volume plasmaexchange: an effective tool in acute liver failure treatment</article-title><source>Int J Artif Organs</source><year>2002</year><volume>25</volume><issue>8</issue><fpage>814</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1177/039139880202500810</pub-id><pub-id pub-id-type="pmid">12296467</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>FS</given-names></name><name><surname>Schmidt</surname><given-names>LE</given-names></name><name><surname>Bernsmeier</surname><given-names>C</given-names></name><name><surname>Rasmussen</surname><given-names>A</given-names></name><name><surname>Isoniemi</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>VC</given-names></name><etal/></person-group><article-title>High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial</article-title><source>J Hepatol</source><year>2016</year><volume>64</volume><issue>1</issue><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.08.018</pub-id><pub-id pub-id-type="pmid">26325537</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mir&#x000f3;</surname><given-names>JM</given-names></name><name><surname>Laguno</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>A</given-names></name><name><surname>Rimola</surname><given-names>A</given-names></name><collab>Hospital Clinic Olt In Hiv Working Group</collab></person-group><article-title>Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><issue>1 Suppl</issue><fpage>S140</fpage><lpage>S145</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.11.028</pub-id><pub-id pub-id-type="pmid">16352366</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asrani</surname><given-names>SK</given-names></name><name><surname>Devarbhavi</surname><given-names>H</given-names></name><name><surname>Eaton</surname><given-names>J</given-names></name><name><surname>Kamath</surname><given-names>PS</given-names></name></person-group><article-title>Burden of liver diseases in the world</article-title><source>J Hepatol</source><year>2019</year><volume>70</volume><issue>1</issue><fpage>151</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.09.014</pub-id><pub-id pub-id-type="pmid">30266282</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name></person-group><article-title>Artificial liver support systems</article-title><source>J Assoc Physicians India</source><year>2004</year><volume>52</volume><fpage>719</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">15839451</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pareja</surname><given-names>E</given-names></name><name><surname>Gomez-Lechon</surname><given-names>MJ</given-names></name><name><surname>Cortes</surname><given-names>M</given-names></name><name><surname>Bonora-Centelles</surname><given-names>A</given-names></name><name><surname>Castell</surname><given-names>JV</given-names></name><name><surname>Mir</surname><given-names>J</given-names></name></person-group><article-title>Human hepatocyte transplantation in patients with hepatic failure awaiting a graft</article-title><source>Eur Surg Res</source><year>2013</year><volume>50</volume><issue>3-4</issue><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1159/000351332</pub-id><pub-id pub-id-type="pmid">23796722</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>TN</given-names></name><name><surname>Zarrinpar</surname><given-names>A</given-names></name></person-group><article-title>Hepatocyte transplantation: past efforts, current technology, and future expansion of therapeutic potential</article-title><source>J Surg Res</source><year>2018</year><volume>226</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2018.01.031</pub-id><pub-id pub-id-type="pmid">29661288</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a Mart&#x000ed;nez</surname><given-names>JJ</given-names></name><name><surname>Bendjelid</surname><given-names>K</given-names></name></person-group><article-title>Artificial liver support systems: what is new over the last decade?</article-title><source>Ann Intensive Care</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/s13613-018-0453-z</pub-id><pub-id pub-id-type="pmid">30443736</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective five-year follow-up study</article-title><source>Transplant Proc</source><year>2014</year><volume>46</volume><issue>1</issue><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2013.10.042</pub-id><pub-id pub-id-type="pmid">24507050</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koelfat</surname><given-names>KVK</given-names></name><name><surname>van Mierlo</surname><given-names>KMC</given-names></name><name><surname>Lodewick</surname><given-names>TM</given-names></name><name><surname>Bloemen</surname><given-names>JG</given-names></name><name><surname>van der Kroft</surname><given-names>G</given-names></name><name><surname>Amygdalos</surname><given-names>I</given-names></name><name><surname>Neumann</surname><given-names>UP</given-names></name><name><surname>Dejong</surname><given-names>CHC</given-names></name><name><surname>Jansen</surname><given-names>PLM</given-names></name><name><surname>Olde Damink</surname><given-names>SWM</given-names></name><name><surname>Schaap</surname><given-names>FG</given-names></name></person-group><article-title>Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration</article-title><source>Hepatol Commun</source><year>2021</year><volume>5</volume><issue>8</issue><fpage>1400</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1002/hep4.1728</pub-id><pub-id pub-id-type="pmid">34430784</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si-Tayeb</surname><given-names>K</given-names></name><name><surname>Noto</surname><given-names>FK</given-names></name><name><surname>Nagaoka</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Battle</surname><given-names>MA</given-names></name><name><surname>Duris</surname><given-names>C</given-names></name><etal/></person-group><article-title>Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><issue>1</issue><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1002/hep.23354</pub-id><pub-id pub-id-type="pmid">19998274</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asumda</surname><given-names>FZ</given-names></name><name><surname>Hatzistergos</surname><given-names>KE</given-names></name><name><surname>Dykxhoorn</surname><given-names>DM</given-names></name><name><surname>Jakubski</surname><given-names>S</given-names></name><name><surname>Edwards</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><etal/></person-group><article-title>Differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules</article-title><source>Differentiation</source><year>2018</year><volume>101</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.diff.2018.03.002</pub-id><pub-id pub-id-type="pmid">29626713</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stravitz</surname><given-names>RT</given-names></name><name><surname>Lee</surname><given-names>WM</given-names></name></person-group><article-title>Acute liver failure</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10201</issue><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(19)31894-x</pub-id><pub-id pub-id-type="pmid">31498101</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Jaeschke</surname><given-names>H</given-names></name></person-group><article-title>Acetaminophen Hepatotoxicity</article-title><source>Semin Liver Dis</source><year>2019</year><volume>39</volume><issue>2</issue><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1055/s-0039-1679919</pub-id><pub-id pub-id-type="pmid">30849782</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akakpo</surname><given-names>JY</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Kandel</surname><given-names>SE</given-names></name><name><surname>Ni</surname><given-names>HM</given-names></name><name><surname>Kumer</surname><given-names>SC</given-names></name><name><surname>Rumack</surname><given-names>BH</given-names></name><etal/></person-group><article-title>4-Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes</article-title><source>Hum Exp Toxicol</source><year>2018</year><volume>37</volume><issue>12</issue><fpage>1310</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1177/0960327118774902</pub-id><pub-id pub-id-type="pmid">29739258</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>K</given-names></name><name><surname>Shimazaki</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>R</given-names></name><name><surname>Izumi</surname><given-names>T</given-names></name><name><surname>Umumura</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name></person-group><article-title>Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection</article-title><source>Ann Transl Med</source><year>2016</year><volume>4</volume><issue>18</issue><fpage>337</fpage><pub-id pub-id-type="doi">10.21037/atm.2016.08.54</pub-id><pub-id pub-id-type="pmid">27761441</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name></person-group><article-title>The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA</article-title><source>Virus Res</source><year>2018</year><volume>244</volume><fpage>304</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.06.010</pub-id><pub-id pub-id-type="pmid">28627393</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laleman</surname><given-names>W</given-names></name><name><surname>Wilmer</surname><given-names>A</given-names></name><name><surname>Evenepoel</surname><given-names>P</given-names></name><name><surname>Verslype</surname><given-names>C</given-names></name><name><surname>Fevery</surname><given-names>J</given-names></name><name><surname>Nevens</surname><given-names>F</given-names></name></person-group><article-title>Review article: non-biological liver support in liver failure</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>23</volume><issue>3</issue><fpage>351</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02765.x</pub-id><pub-id pub-id-type="pmid">16422994</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver</article-title><source>Exp Ther Med</source><year>2016</year><volume>12</volume><issue>6</issue><fpage>3873</fpage><lpage>3876</lpage><pub-id pub-id-type="doi">10.3892/etm.2016.3887</pub-id><pub-id pub-id-type="pmid">28105119</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karvellas</surname><given-names>CJ</given-names></name><name><surname>Gibney</surname><given-names>N</given-names></name><name><surname>Kutsogiannis</surname><given-names>D</given-names></name><name><surname>Wendon</surname><given-names>J</given-names></name><name><surname>Bain</surname><given-names>VG</given-names></name></person-group><article-title>Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure</article-title><source>Crit Care</source><year>2007</year><volume>11</volume><issue>3</issue><fpage>215</fpage><pub-id pub-id-type="doi">10.1186/cc5922</pub-id><pub-id pub-id-type="pmid">17567927</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saliba</surname><given-names>F</given-names></name><name><surname>Samuel</surname><given-names>D</given-names></name></person-group><article-title>Artificial liver support: a real step forward</article-title><source>Minerva Med</source><year>2015</year><volume>106</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">25367058</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>TJ</given-names></name><name><surname>Lillegard</surname><given-names>JB</given-names></name><name><surname>Nyberg</surname><given-names>SL</given-names></name></person-group><article-title>Artificial and bioartificial liver support</article-title><source>Semin Liver Dis</source><year>2008</year><volume>28</volume><issue>2</issue><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1073120</pub-id><pub-id pub-id-type="pmid">18452120</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamuleau</surname><given-names>RA</given-names></name></person-group><article-title>Artificial liver support in the third millennium</article-title><source>Artif Cells Blood Substit Immobil Biotechnol</source><year>2003</year><volume>31</volume><issue>2</issue><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1081/bio-120020168</pub-id><pub-id pub-id-type="pmid">12751830</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Kerkhove</surname><given-names>MP</given-names></name><name><surname>Di Florio</surname><given-names>E</given-names></name><name><surname>Scuderi</surname><given-names>V</given-names></name><name><surname>Mancini</surname><given-names>A</given-names></name><name><surname>Belli</surname><given-names>A</given-names></name><name><surname>Bracco</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver</article-title><source>Cell Transplant</source><year>2003</year><volume>12</volume><issue>6</issue><fpage>563</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14579924</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demetriou</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Busuttil</surname><given-names>RW</given-names></name><name><surname>Fair</surname><given-names>J</given-names></name><name><surname>McGuire</surname><given-names>BM</given-names></name><name><surname>Rosenthal</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure</article-title><source>Ann Surg</source><year>2004</year><volume>239</volume><issue>5</issue><fpage>660</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000124298.74199.e5</pub-id><pub-id pub-id-type="pmid">15082970</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>CT</given-names></name><name><surname>Hickey</surname><given-names>RD</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Mao</surname><given-names>SA</given-names></name><name><surname>Lopera Higuita</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts</article-title><source>Stem Cells</source><year>2017</year><volume>35</volume><issue>1</issue><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1002/stem.2500</pub-id><pub-id pub-id-type="pmid">27641427</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>YT</given-names></name><name><surname>Qi</surname><given-names>YN</given-names></name><name><surname>Zhang</surname><given-names>BQ</given-names></name><name><surname>Li</surname><given-names>JB</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name></person-group><article-title>Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature</article-title><source>World J Gastroenterol</source><year>2019</year><volume>25</volume><issue>27</issue><fpage>3634</fpage><lpage>3648</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i27.3634</pub-id><pub-id pub-id-type="pmid">31367162</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Jang</surname><given-names>YJ</given-names></name><name><surname>An</surname><given-names>SY</given-names></name><name><surname>Son</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><etal/></person-group><article-title>Enhanced Metabolizing Activity of Human ES Cell-Derived Hepatocytes Using a 3D Culture System with Repeated Exposures to Xenobiotics</article-title><source>Toxicol Sci</source><year>2015</year><volume>147</volume><issue>1</issue><fpage>190</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfv121</pub-id><pub-id pub-id-type="pmid">26089346</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>F</given-names></name><name><surname>Freyer</surname><given-names>N</given-names></name><name><surname>Brzeszczynska</surname><given-names>J</given-names></name><name><surname>Kn&#x000f6;spel</surname><given-names>F</given-names></name><name><surname>Armstrong</surname><given-names>L</given-names></name><name><surname>Lako</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hepatic differentiation of human iPSCs in different 3D models: A comparative study</article-title><source>Int J Mol Med</source><year>2017</year><volume>40</volume><issue>6</issue><fpage>1759</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2017.3190</pub-id><pub-id pub-id-type="pmid">29039463</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Direct reprogramming of human fibroblasts to functional and expandable hepatocytes</article-title><source>Cell Stem Cell</source><year>2014</year><volume>14</volume><issue>3</issue><fpage>370</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.01.003</pub-id><pub-id pub-id-type="pmid">24582927</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>CB</given-names></name><name><surname>Pan</surname><given-names>XP</given-names></name><name><surname>Li</surname><given-names>LJ</given-names></name></person-group><article-title>Progress in bioreactors of bioartificial livers</article-title><source>Hepatobiliary Pancreat Dis Int</source><year>2009</year><volume>8</volume><issue>2</issue><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">19357025</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selden</surname><given-names>C</given-names></name><name><surname>Spearman</surname><given-names>CW</given-names></name><name><surname>Kahn</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Figaji</surname><given-names>A</given-names></name><name><surname>Erro</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of encapsulated liver cell spheroids in a fluidised-bed bioartificial liver for treatment of ischaemic acute liver failure in pigs in a translational setting</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e82312</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0082312</pub-id><pub-id pub-id-type="pmid">24367515</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname><given-names>SC</given-names></name><name><surname>Chowdhury</surname><given-names>JR</given-names></name><name><surname>Fox</surname><given-names>IJ</given-names></name></person-group><article-title>Hepatocyte transplantation for the treatment of human disease</article-title><source>Semin Liver Dis</source><year>1999</year><volume>19</volume><issue>1</issue><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1007096</pub-id><pub-id pub-id-type="pmid">10349682</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilir</surname><given-names>BM</given-names></name><name><surname>Guinette</surname><given-names>D</given-names></name><name><surname>Karrer</surname><given-names>F</given-names></name><name><surname>Kumpe</surname><given-names>DA</given-names></name><name><surname>Krysl</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatocyte transplantation in acute liver failure</article-title><source>Liver Transpl</source><year>2000</year><volume>6</volume><issue>1</issue><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/lt.500060113</pub-id><pub-id pub-id-type="pmid">10648575</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name><name><surname>Strom</surname><given-names>SC</given-names></name></person-group><article-title>Human hepatocyte transplantation: worldwide results</article-title><source>Transplantation</source><year>2006</year><volume>82</volume><issue>4</issue><fpage>441</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1097/01.tp.0000231689.44266.ac</pub-id><pub-id pub-id-type="pmid">16926585</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyburg</surname><given-names>J</given-names></name><name><surname>Hoerster</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>Poeschl</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>GF</given-names></name><name><surname>Schenk</surname><given-names>JP</given-names></name></person-group><article-title>Monitoring of intraportal liver cell application in children</article-title><source>Cell Transplant</source><year>2010</year><volume>19</volume><issue>5</issue><fpage>629</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.3727/096368909x485058</pub-id><pub-id pub-id-type="pmid">20053320</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name><name><surname>Bu</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Tisnado</surname><given-names>J</given-names></name><name><surname>Prasad</surname><given-names>U</given-names></name><name><surname>Sterling</surname><given-names>R</given-names></name><etal/></person-group><article-title>Defining hepatocellular chimerism in a liver failure patient bridged with hepatocyte infusion</article-title><source>Transplantation</source><year>2000</year><volume>69</volume><issue>2</issue><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1097/00007890-200001270-00018</pub-id><pub-id pub-id-type="pmid">10670643</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iansante</surname><given-names>V</given-names></name><name><surname>Mitry</surname><given-names>RR</given-names></name><name><surname>Filippi</surname><given-names>C</given-names></name><name><surname>Fitzpatrick</surname><given-names>E</given-names></name><name><surname>Dhawan</surname><given-names>A</given-names></name></person-group><article-title>Human hepatocyte transplantation for liver disease: current status and future perspectives</article-title><source>Pediatr Res</source><year>2018</year><volume>83</volume><issue>1-2</issue><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/pr.2017.284</pub-id><pub-id pub-id-type="pmid">29149103</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>MC</given-names></name><name><surname>Gramignoli</surname><given-names>R</given-names></name><name><surname>Skvorak</surname><given-names>KJ</given-names></name><name><surname>Dorko</surname><given-names>K</given-names></name><name><surname>Marongiu</surname><given-names>F</given-names></name><name><surname>Blake</surname><given-names>W</given-names></name><etal/></person-group><article-title>The history and use of human hepatocytes for the treatment of liver diseases: the first 100 patients</article-title><source>Curr Protoc Toxicol</source><year>2014</year><volume>62</volume><fpage>14.12.1</fpage><lpage>14.1223</lpage><pub-id pub-id-type="doi">10.1002/0471140856.tx1412s62</pub-id><pub-id pub-id-type="pmid">25378242</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flohr</surname><given-names>TR</given-names></name><name><surname>Bonatti</surname><given-names>H</given-names><suffix>Jr</suffix></name><name><surname>Brayman</surname><given-names>KL</given-names></name><name><surname>Pruett</surname><given-names>TL</given-names></name></person-group><article-title>The use of stem cells in liver disease</article-title><source>Curr Opin Organ Transplant</source><year>2009</year><volume>14</volume><issue>1</issue><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/MOT.0b013e328320fd7b</pub-id><pub-id pub-id-type="pmid">19337149</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallanna</surname><given-names>SK</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name></person-group><article-title>Differentiation of hepatocytes from pluripotent stem cells</article-title><source>Curr Protoc Stem Cell Biol</source><year>2013</year><volume>26</volume><fpage>1G.4.1</fpage><lpage>1G.4.13</lpage><pub-id pub-id-type="doi">10.1002/9780470151808.sc01g04s26</pub-id><pub-id pub-id-type="pmid">24510789</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Ang</surname><given-names>J</given-names></name><name><surname>Auyeong</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>Efficient endoderm induction from human pluripotent stem cells by logically directing signals controlling lineage bifurcations</article-title><source>Cell Stem Cell</source><year>2014</year><volume>14</volume><issue>2</issue><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.12.007</pub-id><pub-id pub-id-type="pmid">24412311</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>JY</given-names></name><name><surname>Sriram</surname><given-names>G</given-names></name><name><surname>Rufaihah</surname><given-names>AJ</given-names></name><name><surname>Neoh</surname><given-names>KG</given-names></name><name><surname>Cao</surname><given-names>T</given-names></name></person-group><article-title>Efficient derivation of lateral plate and paraxial mesoderm subtypes from human embryonic stem cells through GSKi-mediated differentiation</article-title><source>Stem Cells Dev</source><year>2013</year><volume>22</volume><issue>13</issue><fpage>1893</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1089/scd.2012.0590</pub-id><pub-id pub-id-type="pmid">23413973</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannan</surname><given-names>NR</given-names></name><name><surname>Segeritz</surname><given-names>CP</given-names></name><name><surname>Touboul</surname><given-names>T</given-names></name><name><surname>Vallier</surname><given-names>L</given-names></name></person-group><article-title>Production of hepatocyte-like cells from human pluripotent stem cells</article-title><source>Nat Protoc</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>430</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.153</pub-id><pub-id pub-id-type="pmid">23424751</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AM</given-names></name><name><surname>Reynolds</surname><given-names>D</given-names></name><name><surname>Cliff</surname><given-names>T</given-names></name><name><surname>Ohtsuka</surname><given-names>S</given-names></name><name><surname>Mattheyses</surname><given-names>AL</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation</article-title><source>Cell Stem Cell</source><year>2012</year><volume>10</volume><issue>3</issue><fpage>312</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.01.014</pub-id><pub-id pub-id-type="pmid">22385658</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tafaleng</surname><given-names>EN</given-names></name><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Hale</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Soto-Gutierrez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Induced pluripotent stem cells model personalized variations in liver disease resulting from &#x003b1;1-antitrypsin deficiency</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><issue>1</issue><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1002/hep.27753</pub-id><pub-id pub-id-type="pmid">25690322</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borowiak</surname><given-names>M</given-names></name><name><surname>Maehr</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>AE</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Fox</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells</article-title><source>Cell Stem Cell</source><year>2009</year><volume>4</volume><issue>4</issue><fpage>348</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2009.01.014</pub-id><pub-id pub-id-type="pmid">19341624</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touboul</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>To</surname><given-names>CC</given-names></name><name><surname>Mora-Castilla</surname><given-names>S</given-names></name><name><surname>Sabatini</surname><given-names>K</given-names></name><name><surname>Tukey</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Stage-specific regulation of the WNT/&#x003b2;-catenin pathway enhances differentiation of hESCs into hepatocytes</article-title><source>J Hepatol</source><year>2016</year><volume>64</volume><issue>6</issue><fpage>1315</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.02.028</pub-id><pub-id pub-id-type="pmid">26921690</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>N</given-names></name><etal/></person-group><article-title>Highly efficient and expedited hepatic differentiation from human pluripotent stem cells by pure small-molecule cocktails</article-title><source>Stem Cell Res Ther</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s13287-018-0794-4</pub-id><pub-id pub-id-type="pmid">29523187</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Getachew</surname><given-names>A</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Robust expansion and functional maturation of human hepatoblasts by chemical strategy</article-title><source>Stem Cell Res Ther</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>151</fpage><pub-id pub-id-type="doi">10.1186/s13287-021-02233-9</pub-id><pub-id pub-id-type="pmid">33632328</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Cen</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><etal/></person-group><article-title>In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity</article-title><source>Cell Stem Cell</source><year>2018</year><volume>23</volume><issue>6</issue><fpage>806</fpage><lpage>819.e4</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.10.018</pub-id><pub-id pub-id-type="pmid">30416071</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagida</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Chikada</surname><given-names>H</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><name><surname>Kamiya</surname><given-names>A</given-names></name></person-group><article-title>An in vitro expansion system for generation of human iPS cell-derived hepatic progenitor-like cells exhibiting a bipotent differentiation potential</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>7</issue><fpage>e67541</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0067541</pub-id><pub-id pub-id-type="pmid">23935837</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Self-renewal of hepatoblasts under chemically defined conditions by iterative growth factor and chemical screening</article-title><source>Hepatology</source><year>2015</year><volume>61</volume><issue>1</issue><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1002/hep.27421</pub-id><pub-id pub-id-type="pmid">25203445</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Generation of Self-Renewing Hepatoblasts From Human Embryonic Stem Cells by Chemical Approaches</article-title><source>Stem Cells Transl Med</source><year>2015</year><volume>4</volume><issue>11</issue><fpage>1275</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.5966/sctm.2015-0051</pub-id><pub-id pub-id-type="pmid">26371343</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Synergistic modulation of signaling pathways to expand and maintain the bipotency of human hepatoblasts</article-title><source>Stem Cell Res Ther</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>364</fpage><pub-id pub-id-type="doi">10.1186/s13287-019-1463-y</pub-id><pub-id pub-id-type="pmid">31791391</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huch</surname><given-names>M</given-names></name><name><surname>Gehart</surname><given-names>H</given-names></name><name><surname>van Boxtel</surname><given-names>R</given-names></name><name><surname>Hamer</surname><given-names>K</given-names></name><name><surname>Blokzijl</surname><given-names>F</given-names></name><name><surname>Verstegen</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Long-term culture of genome-stable bipotent stem cells from adult human liver</article-title><source>Cell</source><year>2015</year><volume>160</volume><issue>1-2</issue><fpage>299</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.11.050</pub-id><pub-id pub-id-type="pmid">25533785</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>Seo</surname><given-names>D</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells</article-title><source>J Hepatol</source><year>2019</year><volume>70</volume><issue>1</issue><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.09.007</pub-id><pub-id pub-id-type="pmid">30240598</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Kurimoto</surname><given-names>Y</given-names></name><name><surname>Hirami</surname><given-names>Y</given-names></name><name><surname>Morinaga</surname><given-names>C</given-names></name><name><surname>Daimon</surname><given-names>T</given-names></name><etal/></person-group><article-title>Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><issue>11</issue><fpage>1038</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1608368</pub-id><pub-id pub-id-type="pmid">28296613</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Possamai</surname><given-names>LA</given-names></name><name><surname>Thursz</surname><given-names>MR</given-names></name><name><surname>Wendon</surname><given-names>JA</given-names></name><name><surname>Antoniades</surname><given-names>CG</given-names></name></person-group><article-title>Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><issue>2</issue><fpage>439</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.03.031</pub-id><pub-id pub-id-type="pmid">24703954</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triantafyllou</surname><given-names>E</given-names></name><name><surname>Woollard</surname><given-names>KJ</given-names></name><name><surname>McPhail</surname><given-names>MJW</given-names></name><name><surname>Antoniades</surname><given-names>CG</given-names></name><name><surname>Possamai</surname><given-names>LA</given-names></name></person-group><article-title>The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>2948</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02948</pub-id><pub-id pub-id-type="pmid">30619308</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barclay</surname><given-names>AN</given-names></name><name><surname>Van den Berg</surname><given-names>TK</given-names></name></person-group><article-title>The interaction between signal regulatory protein alpha (SIRP&#x003b1;) and CD47: structure, function, and therapeutic target</article-title><source>Annu Rev Immunol</source><year>2014</year><volume>32</volume><fpage>25</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120142</pub-id><pub-id pub-id-type="pmid">24215318</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayat</surname><given-names>SMG</given-names></name><name><surname>Bianconi</surname><given-names>V</given-names></name><name><surname>Pirro</surname><given-names>M</given-names></name><name><surname>Jaafari</surname><given-names>MR</given-names></name><name><surname>Hatamipour</surname><given-names>M</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group><article-title>CD47: role in the immune system and application to cancer therapy</article-title><source>Cell Oncol (Dordr)</source><year>2020</year><volume>43</volume><issue>1</issue><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s13402-019-00469-5</pub-id><pub-id pub-id-type="pmid">31485984</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logtenberg</surname><given-names>MEW</given-names></name><name><surname>Scheeren</surname><given-names>FA</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name></person-group><article-title>The CD47-SIRP&#x003b1; Immune Checkpoint</article-title><source>Immunity</source><year>2020</year><volume>52</volume><issue>5</issue><fpage>742</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.011</pub-id><pub-id pub-id-type="pmid">32433947</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>CS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>ASL</given-names></name><name><surname>Lui</surname><given-names>KO</given-names></name></person-group><article-title>Ectopic expression of recipient CD47 inhibits mouse macrophage-mediated immune rejection against human stem cell transplants</article-title><source>FASEB J</source><year>2019</year><volume>33</volume><issue>1</issue><fpage>484</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1096/fj.201800449R</pub-id><pub-id pub-id-type="pmid">30004796</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyvazian</surname><given-names>VA</given-names></name><name><surname>Gordin</surname><given-names>JS</given-names></name><name><surname>Yang</surname><given-names>EH</given-names></name><name><surname>Aksoy</surname><given-names>O</given-names></name><name><surname>Honda</surname><given-names>HM</given-names></name><name><surname>Busuttil</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Incidence, Predictors, and Outcomes of New-Onset Left Ventricular Systolic Dysfunction After Orthotopic Liver Transplantation</article-title><source>J Card Fail</source><year>2019</year><volume>25</volume><issue>3</issue><fpage>166</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2018.10.013</pub-id><pub-id pub-id-type="pmid">30412734</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addeo</surname><given-names>P</given-names></name><name><surname>Noblet</surname><given-names>V</given-names></name><name><surname>Naegel</surname><given-names>B</given-names></name><name><surname>Bachellier</surname><given-names>P</given-names></name></person-group><article-title>Large-for-Size Orthotopic Liver Transplantation: a Systematic Review of Definitions, Outcomes, and Solutions</article-title><source>J Gastrointest Surg</source><year>2020</year><volume>24</volume><issue>5</issue><fpage>1192</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1007/s11605-019-04505-5</pub-id><pub-id pub-id-type="pmid">31919740</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolosa</surname><given-names>L</given-names></name><name><surname>Pareja</surname><given-names>E</given-names></name><name><surname>G&#x000f3;mez-Lech&#x000f3;n</surname><given-names>MJ</given-names></name></person-group><article-title>Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?</article-title><source>Transplantation</source><year>2016</year><volume>100</volume><issue>12</issue><fpage>2548</fpage><lpage>2557</lpage><pub-id pub-id-type="doi">10.1097/tp.0000000000001426</pub-id><pub-id pub-id-type="pmid">27495745</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Luce</surname><given-names>E</given-names></name><name><surname>Hussein</surname><given-names>M</given-names></name><name><surname>Dubart-Kupperschmitt</surname><given-names>A</given-names></name></person-group><article-title>Pluripotent-Stem-Cell-Derived Hepatic Cells: Hepatocytes and Organoids for Liver Therapy and Regeneration</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>E420</fpage><pub-id pub-id-type="doi">10.3390/cells9020420</pub-id><pub-id pub-id-type="pmid">32059501</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mun</surname><given-names>SJ</given-names></name><name><surname>Ryu</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>MO</given-names></name><name><surname>Son</surname><given-names>YS</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Cho</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids</article-title><source>J Hepatol</source><year>2019</year><volume>71</volume><issue>5</issue><fpage>970</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.030</pub-id><pub-id pub-id-type="pmid">31299272</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>Induced Pluripotent Stem Cells Meet Genome Editing</article-title><source>Cell Stem Cell</source><year>2016</year><volume>18</volume><issue>5</issue><fpage>573</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.04.013</pub-id><pub-id pub-id-type="pmid">27152442</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>MN</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Truong</surname><given-names>VA</given-names></name><name><surname>Lai</surname><given-names>PL</given-names></name><name><surname>Nguyen</surname><given-names>TKN</given-names></name><name><surname>Hu</surname><given-names>YC</given-names></name></person-group><article-title>CRISPR technologies for stem cell engineering and regenerative medicine</article-title><source>Biotechnol Adv</source><year>2019</year><volume>37</volume><issue>8</issue><fpage>107447</fpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2019.107447</pub-id><pub-id pub-id-type="pmid">31513841</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>SB</given-names></name><name><surname>Inuzuka</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>JN</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genetically edited hepatic cells expressing the NTCP-S267F variant are resistant to hepatitis B virus infection</article-title><source>Mol Ther Methods Clin Dev</source><year>2021</year><volume>23</volume><fpage>597</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2021.11.002</pub-id><pub-id pub-id-type="pmid">34853804</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name></person-group><article-title>Advances in HBV infection and replication systems in vitro</article-title><source>Virol J</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s12985-021-01580-6</pub-id><pub-id pub-id-type="pmid">34051803</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shani</surname><given-names>T</given-names></name><name><surname>Hanna</surname><given-names>JH</given-names></name></person-group><article-title>Universally non-immunogenic iPSCs</article-title><source>Nat Biomed Eng</source><year>2019</year><volume>3</volume><issue>5</issue><fpage>337</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/s41551-019-0401-8</pub-id><pub-id pub-id-type="pmid">31036889</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Kagita</surname><given-names>A</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Sasakawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility</article-title><source>Cell Stem Cell</source><year>2019</year><volume>24</volume><issue>4</issue><fpage>566</fpage><lpage>578.e7</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.02.005</pub-id><pub-id pub-id-type="pmid">30853558</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Repair of acute liver damage with immune evasive hESC derived hepato-blasts</article-title><source>Stem Cell Res</source><year>2020</year><volume>49</volume><fpage>102010</fpage><pub-id pub-id-type="doi">10.1016/j.scr.2020.102010</pub-id><pub-id pub-id-type="pmid">33011360</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Stradner</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>H</given-names></name><etal/></person-group><article-title>An effective approach to prevent immune rejection of human ESC-derived allografts</article-title><source>Cell Stem Cell</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.11.014</pub-id><pub-id pub-id-type="pmid">24388175</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dissegna</surname><given-names>D</given-names></name><name><surname>Sponza</surname><given-names>M</given-names></name><name><surname>Falleti</surname><given-names>E</given-names></name><name><surname>Fabris</surname><given-names>C</given-names></name><name><surname>Vit</surname><given-names>A</given-names></name><name><surname>Angeli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis</article-title><source>Eur J Gastroenterol Hepatol</source><year>2019</year><volume>31</volume><issue>5</issue><fpage>626</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1097/meg.0000000000001342</pub-id><pub-id pub-id-type="pmid">30550458</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwyer</surname><given-names>BJ</given-names></name><name><surname>Macmillan</surname><given-names>MT</given-names></name><name><surname>Brennan</surname><given-names>PN</given-names></name><name><surname>Forbes</surname><given-names>SJ</given-names></name></person-group><article-title>Cell therapy for advanced liver diseases: Repair or rebuild</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><issue>1</issue><fpage>185</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.09.014</pub-id><pub-id pub-id-type="pmid">32976865</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moniaux</surname><given-names>N</given-names></name><name><surname>Faivre</surname><given-names>J</given-names></name></person-group><article-title>Will nano-fibers permit to turn liver cell transplantation into a curative tool against liver failure?</article-title><source>J Hepatol</source><year>2010</year><volume>52</volume><issue>2</issue><fpage>150</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2009.10.027</pub-id><pub-id pub-id-type="pmid">20006401</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yi</surname><given-names>K</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure</article-title><source>Nanomicro Lett</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>25</fpage><pub-id pub-id-type="doi">10.1007/s40820-020-00550-x</pub-id><pub-id pub-id-type="pmid">34138224</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>A</given-names></name><name><surname>Chaijitraruch</surname><given-names>N</given-names></name><name><surname>Fitzpatrick</surname><given-names>E</given-names></name><name><surname>Bansal</surname><given-names>S</given-names></name><name><surname>Filippi</surname><given-names>C</given-names></name><name><surname>Lehec</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><issue>5</issue><fpage>877</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.12.002</pub-id><pub-id pub-id-type="pmid">31843649</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqua</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>U</given-names></name><name><surname>de Lartigue</surname><given-names>C</given-names></name><name><surname>Nicolas</surname><given-names>J</given-names></name><name><surname>Vigneron</surname><given-names>P</given-names></name><name><surname>Dermigny</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Preclinical characterization of alginate-poly-L-lysine encapsulated HepaRG for extracorporeal liver supply</article-title><source>Biotechnol Bioeng</source><year>2021</year><volume>118</volume><issue>1</issue><fpage>453</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/bit.27583</pub-id><pub-id pub-id-type="pmid">32997339</pub-id></element-citation></ref><ref id="JCTH-D-21-00353-b92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>HF</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>D</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Stem cell therapy and tissue engineering strategies using cell aggregates and decellularized scaffolds for the rescue of liver failure</article-title><source>J Tissue Eng</source><year>2021</year><volume>12</volume><fpage>2041731420986711</fpage><pub-id pub-id-type="doi">10.1177/2041731420986711</pub-id><pub-id pub-id-type="pmid">35003615</pub-id></element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>ALF</term><def><p>Acute liver failure</p></def></def-item><def-item><term>BAL</term><def><p>Bioartificial liver</p></def></def-item><def-item><term>DE</term><def><p>Definitive endoderm</p></def></def-item><def-item><term>HB</term><def><p>Hepatoblast</p></def></def-item><def-item><term>hESC</term><def><p>Human embryonic stem cell</p></def></def-item><def-item><term>HLC</term><def><p>Hepatic like cell</p></def></def-item><def-item><term>HT</term><def><p>Hepatocytes Transplantation</p></def></def-item><def-item><term>iPSC</term><def><p>induced pluripotent stem cell</p></def></def-item><def-item><term>OLT</term><def><p>Orthotopic liver transplantation</p></def></def-item><def-item><term>PH</term><def><p>Primary hepatocytes</p></def></def-item><def-item><term>PSC</term><def><p>Pluripotent stem cell</p></def></def-item></def-list></glossary></back></article>
